Chester County News and Community Website
WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory …
FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma Read More
WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …
MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More
KING OF PRUSSIA, PA — SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., has announced a major advancement in oncology with the discovery of PVTX-405, a potent …
SK Life Science Labs Unveils Breakthrough in Cancer Therapy with PVTX-405 Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its …
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss …
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances Read More WILMINGTON, DE — AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer (MIBC), making it the first perioperative immunotherapy available in the U.S. …
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer Read More
CHEYNEY, PA — Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) development to target cancers that overexpress the humoral immunosuppressive oncology (HIO) factor ICAM-1. The …
Navrogen Advances Antibody Technology to Combat Cancer with New Findings Read More
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
SPRING HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to …
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study Read More